生长分化因子-15预测心脏骤停后生存不良
这项前瞻性观察研究纳入128例院内外心脏骤停后恢复自主循环并住 tertiary university hospital 的患者,入院时测定血清GDF-15。6个月随访52例(40.6%)死亡,死亡者GDF-15中位数3172 ng/L显著高于存活者1601 ng/L(p<0.001);神经功能不良(CPC 3-5)者GDF-15也显著高于CPC 1-2者(p<0.001)。单因素Cox回归每增加1个标准差HR 1.76(95%CI 1.35-2.31),多因素校正后HR 1.57(95%CI 1.19-2.07,p=0.001),院内外亚组均见关联。GDF-15可能反映缺氧性脑及多器官损伤程度,有助于改善心脏骤停后早期风险分层。
要点
- 心脏骤停复苏后患者入院时GDF-15越高,6个月死亡风险越高:多因素校正后每增加1个标准差HR 1.57(95%CI 1.19-2.07,p=0.001)。
- 6个月死亡者入院GDF-15中位数3172 ng/L,显著高于存活者1601 ng/L(p<0.001)。
- 神经功能不良(CPC 3-5)者GDF-15显著高于神经功能良好(CPC 1-2)者(p<0.001)。
- GDF-15与6个月结局的关联在院内心脏骤停和院外心脏骤停患者中均存在。
- GDF-15可能反映缺氧对脑及其他器官的损伤程度,可能有助于改善心脏骤停后早期风险分层。
适用人群与场景
- 院内心脏骤停或院外心脏骤停后恢复自主循环、住 tertiary university hospital 的连续患者,共128例,中位年龄60.3岁,75.8%为男性。
研究设计与关键结果
- 前瞻性观察研究,纳入128例心脏骤停后恢复自主循环患者,入院时测定血清GDF-15,随访6个月。
- 6个月随访期间52例(40.6%)死亡;死亡者GDF-15中位数3172 ng/L(四分位距1927-8340 ng/L),存活者1601 ng/L(1114-2983 ng/L),p<0.001。
- 神经功能不良(CPC 3-5)者GDF-15显著高于神经功能良好(CPC 1-2)者,p<0.001。
- 单因素Cox回归:GDF-15每增加1个标准差,6个月死亡HR 1.76(95%CI 1.35-2.31,p<0.001)。
- 多因素校正后:GDF-15每增加1个标准差,6个月死亡HR 1.57(95%CI 1.19-2.07,p=0.001)。
- 亚组分析显示GDF-15与6个月结局的关联在院内心脏骤停和院外心脏骤停患者中均存在。
证据类型、等级与局限
- 证据类型:前瞻性观察研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为GDF-15可能反映缺氧对脑及其他器官的损伤程度,并可能有助于改善心脏骤停后早期风险分层。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Early prognostication in post-cardiac arrest (CA) patients remains challenging and biomarkers have evolved as helpful tools in risk assessment. The stress-response cytokine growth differentiation factor-15 (GDF-15) is dramatically up-regulated during various kinds of tissue injury and predicts outcome in many pathological conditions. We aimed to assess the predictive value of circulating GDF-15 in post-CA patients.
METHODS: This prospective observational study included 128 consecutive patients (median age 60.3 years, 75.8% male) with return of spontaneous circulation after in- or out-of-hospital CA who were treated at a tertiary university hospital. GDF-15 serum levels were determined at admission.
RESULTS: A total of 52 patients (40.6%) died during the 6-month follow-up. Median GDF-15 levels were significantly lower in survivors (1601 ng/L (interquartile range: 1114-2983 ng/L) than in non-survivors (3172 ng/L (1927-8340 ng/L); p < 0.001). GDF-15 levels were also significantly lower in patients with favourable neurological 6-month outcome (cerebral performance category (CPC) 1-2) than in those with poor neurological outcome (CPC 3-5; p < 0.001). GDF-15 significantly predicted 6-month mortality in univariate Cox regression analysis (hazard ratio (HR) per 1-standard deviation increase 1.76 [95% confidence interval (CI) 1.35-2.31; p < 0.001] and remained significant after multivariable adjustment (HR 1.57 [95% CI 1.19-2.07; p = 0.001]). Subgroup analysis revealed that the association between GDF-15 and 6-month outcome was present both in patients with in- and out-of-hospital CA.
CONCLUSIONS: GDF-15 predicts poor survival and neurological outcome in post-CA patients. GDF-15 may reflect the extent of hypoxic injury to the brain and other organs and might help to improve early risk stratification after CA.
参考来源
- Richter B, Uray T, Krychtiuk KA, et al. Growth differentiation factor-15 predicts poor survival after cardiac arrest. Resuscitation. 2019. PMID: 31394153. doi:10.1016/j.resuscitation.2019.07.028
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。